Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.58 |
| ▸ | HTR1A | P08908 | 13/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597071 | 0.92 | MTNR1A (0.59) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL7522246 | 0.90 | MTNR1A (0.60) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL6575956 | 0.83 | MTNR1A (0.58) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL7481895 | 0.83 | MTNR1A (0.58) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL13202088 | 0.83 | MTNR1A (0.65) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL8667866 | 0.83 | MTNR1A (0.58) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL8584312 | 0.83 | MTNR1A (0.60) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL6173819 | 0.82 | MTNR1A (0.59) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL13534264 | 0.82 | MTNR1A (0.64) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A | |
| SCHEMBL13197080 | 0.81 | MTNR1A (0.59) | MTNR1AHTR1ASLC6A4CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2828238-B1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP ZOO (PL) | 2016-05-25 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150051257-A1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. ZO.O (PL) | 2015-02-19 | — | — | US | disclosed |
| EP-2828238-A1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | Adamed Sp. z o.o. (PL) | 2015-01-28 | — | — | EP | disclosed |
| US-20140135310-A1 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2014-05-15 | — | — | US | disclosed |
| EP-2726476-A2 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Adamed sp. z o.o. (PL) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013140347-A1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013001505-A2 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2013-01-03 | — | — | WO | disclosed |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| EP-0873993-B1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-02-20 | — | — | EP | disclosed |
| WO-2001017993-A1 | ALKYLPIPERIDI NYLBENZO [D] ISOXAZOLE DERIVATIVES HAVING PSYCHOTROPIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 2001-03-15 | — | — | WO | disclosed |
| US-5919814-A | Heterocyclic compounds | ADIR ET COMPAGNIE (FR) | 1999-07-06 | — | — | US | disclosed |
| EP-0873993-A1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051257-A1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | AQP4, BCL6, STS | MTNR1A 810/4885HTR1A 742/4885SLC6A4 128/4885 |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | MTNR1A 227/4885HTR1A 141/4885SLC6A4 579/4885 |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | MTNR1A 227/4885HTR1A 141/4885SLC6A4 579/4885 |
| US-20140135310-A1 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | DDC, INA, SCN5A | MTNR1A 1058/4885HTR1A 646/4885SLC6A4 137/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | MTNR1A 149/4885HTR1A 136/4885SLC6A4 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.